Talisman Metals PLC

TLM

IE000XRZAWV1

Biotechnology & Medical Research

Market Closed - London S.E. Other stock markets 11:35:13 2026-03-06 am EST			5-day change	1st Jan Change
9.500 ^GBX	0.00%		-7.32%	+175.36%

Feb. 24	Talisman Metals acquires two Morocco copper licences for GBP16,000	AN
Feb. 24	Talisman Metals Starts Exploration at Fougnar Copper-silver Project in Morocco	MT

Talisman Metals PLC will Change its Ticker to TLM from OVB

Published on 02/06/2026 at 02:50 pm EST

S&P Capital IQ

TALISMAN METALS PLC

0.00%

Effective February 06, 2026, Talisman Metals PLC will change its London Stock Exchange AIM Market stock ticker symbol to TLM from OVB.

Latest news about Talisman Metals PLC

Feb. 24	Talisman Metals acquires two Morocco copper licences for GBP16,000	AN
Feb. 24	Talisman Metals Starts Exploration at Fougnar Copper-silver Project in Morocco	MT
Feb. 24	Talisman Metals plc Announces Commencement of Exploration Work At Fougnar Cu-Ag Project	CI
Feb. 16	Talisman Metals to Buy Tirzzit Copper Project in Morocco	MT
Feb. 16	Talisman Metals PLC Signs an Agreement to Acquire the Tirzzit Copper Project from Aya Silver & Gold Inc	CI
Feb. 10	Talisman Metals PLC Appoints Fabien Linares as Head Geologist	CI
Feb. 06	Talisman Metals PLC will Change its Ticker to TLM from OVB	CI
Jan. 28	Ovoca Bio Finalizes Reverse Takeover of Tadeen International	MT
Jan. 27	Ovoca Bio PLC has Changed its Name to Talisman Metals PLC	CI
Dec. 31	Ovoca Bio seals reverse takeover to become copper explorer Talisman	AN
Nov. 12	Ovoca Bio plc acquired Tadeen International Limited.	CI
25-09-30	Ovoca Bio plc Reports Earnings Results for the Half Year Ended June 30, 2025	CI
25-09-30	EARNINGS: GENinCode sees annual revenue growth slower than expected	AN
25-06-26	EARNINGS: Majestic profit rises; electricity price hike hits Steppe	AN
25-06-24	Ovoca Bio plc Auditor Raises 'Going Concern' Doubt	CI

Ovoca Bio PLC is a clinical-stage biopharmaceutical company focused on womenâ€™s health. The Company is developing Orenetide, a novel medicinal treatment for premenopausal women with hypoactive sexual desire disorder (HSDD). It is focused on womenâ€™s health and identifying novel candidates in areas of high unmet medical need. The Companyâ€™s lead product, Orenetide (BP-101), is a novel synthetic peptide for the treatment of HSDD and is conveniently administered through a nasal spray. The spray delivers the drug to olfactory and trigeminal nerves in the nasal cavity where the drug accumulates in the olfactory bulb and further in the brain. It is also developing a new treatment for women affected by low libido or sex drive. It owns a patent portfolio that provides effective protection of its technology. The Company operates in Ireland, the United Kingdom and Russia.

Employees

Sector

Biotechnology & Medical Research

More about the company